1. Ticagrelor led to a smaller 30-day cardiac magnetic resonance (CMR)-defined infarct size than clopidogrel in pharmaco-invasive STEMI Evidence Rating ...
Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with ...
1. At one month, ticagrelor was not superior to twice-daily clopidogrel in reducing major adverse cardiovascular events (MACEs) in adult ...
Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes 1. In patients with type 2 diabetes (T2D), ...
1. A randomized controlled trial by Lin and colleagues compared artificial intelligence (AI) to standard care in triaging suspected cases ...
1. In this randomized controlled trial, in patients with infarct-relate cardiogenic shock, death from any cause was lower in the ...
1. Patients with ST-elevation myocardial infarction (STEMI) with nonobstructive coronary arteries (MINOCA) and MINOCA-mimicking disease demonstrated significantly higher five-year mortality ...
1. Major adverse cardiovascular events (MACE) were more likely to occur in patients with myocardial infarction (MI) with an optical ...
1. The immediate revascularization group met the noninferiority criteria for the primary composite outcome, but superiority at the 1-year follow-up ...
1. In patients with diabetes mellitus who are on therapy with clopidogrel following percutaneous coronary intervention, high platelet reactivity was ...
